The investment picture
Understand the business. Put the price in context.
The model estimate is 74.0% below the stored share price. Strong operating metrics can still come at a demanding price.
Explore the modelsRevenue
Dec 2025 vs Dec 2024
Reported revenue: ₹484 CrNet profit
Dec 2025 vs Dec 2024
Reported net profit: ₹28 CrProfit into cash
Operating cash flow / net profit
Matched annual period: Mar 2025₹0.27 of operating cash for each ₹1 of reported profit.
Latest-quarter profit rose 3.7% year on year; profit across the last four reported quarters fell 21.3%. Read the latest quarter alongside the longer trend.
Reporting gap · Check newer company filings
Annual: Mar 2025 · Quarterly: Dec 2025 · Cash flow: Mar 2026. These sections refresh independently. A recent price update does not mean the financial statements are current.
Sources: Company data source. Check the company filings linked by the source for the reporting basis and exceptional items.
Valuation models
P/E (56.2) × ROE (5.3%) × BV (₹22.80) × 0.8 × (1 + dividend yield 0.17%)
| Model | Category | Value | Weight | Signal |
|---|---|---|---|---|
| PE-ROE | Earnings | ₹53.04 | 22% | Over (-55.8%) |
| Graham Number | Earnings | ₹30.56 | 16% | Over (-74.5%) |
| Earnings Power | Earnings | ₹9.99 | 13% | Over (-91.7%) |
| DCF | Cash Flow | ₹14.92 | 13% | Over (-87.6%) |
| Net Asset Value | Assets | ₹22.70 | 7% | Over (-81.1%) |
| EV/EBITDA | Enterprise | ₹33.16 | 9% | Over (-72.4%) |
| Earnings Yield | Earnings | ₹18.20 | 7% | Over (-84.8%) |
| ROCE Capital | Returns | ₹48.71 | 9% | Over (-59.4%) |
| Revenue Multiple | Revenue | ₹32.98 | 5% | Over (-72.5%) |
| Consensus (9 models) | ₹31.25 | 100% | Overvalued | |
PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -3.1%
Margin of safety = (model value − price) ÷ model value. The agreement score is a heuristic based on model count, direction and spread; it is not a probability of accuracy. These models are estimates, not price targets.
Estimates depend on assumptions. Compare the model range and verify fresh filings.
Analysis summary
Data coverage: Price-data record updated 25 September 2026, 9:00 pm +05:30. Annual results through Mar 2025; quarterly results through Dec 2025; cash flow through Mar 2026. Each section can have a different reporting period. The share price is not live.
Valuation in context
Morepen Laboratories Ltd: the stored intrinsic value estimate is ₹31.25, compared with a stored share price of ₹120.00. The model value is 74.0% below that quote. The model classifies this as overvalued; it is an estimate dependent on the inputs and assumptions, not a price target or a buy/sell recommendation.
Operating performance
Revenue for Mar 2025 was ₹1,812.00 Cr, versus ₹1,690.00 Cr in Mar 2024 (7.2% year on year). Net profit for Mar 2025 was ₹118.00 Cr, versus ₹97.00 Cr in Mar 2024 (21.6% year on year). These are the latest annual periods stored on this page; check the quarterly table separately for more recent developments.
Cash generation
For the same Mar 2025 period, operating cash flow was ₹32.00 Cr against net profit of ₹118.00 Cr. Cash flow covered 0.27 times reported profit. The gap warrants checking receivables, working capital and one-off items in the cash-flow statement.
Balance-sheet check
Reported borrowings were ₹208.00 Cr in Mar 2026. Read this alongside cash, interest costs and repayment obligations; reserves are an accounting balance and are not the same as available cash.
How to use the valuation and peer comparisons
The Intrinsic Value panel combines the available model estimates using the displayed weights. Earnings, cash-flow, dividend and asset-based methods can give very different answers. The displayed 12% cost of equity and 4% terminal growth assumptions apply where relevant; historical EPS growth is not a promise of future growth. Use the individual values and their spread to judge sensitivity.
The peer group follows the stored industry classification and may include different business models. Compare reporting periods, leverage and recurring earnings before interpreting a valuation gap. For banks and other financial businesses, capital adequacy and asset quality can be more informative than industrial-company cash-flow ratios.
Sources: Company data source. Check the company filings linked by the source for the reporting basis and exceptional items.
Automatically generated interpretation of the stored financial data, not a separately researched analyst opinion. Missing data is not evidence of poor performance. New filings become available here after the existing data refresh process captures them.
Business quality
Data coverage: 5/5 dimensions. Financial reporting periods vary by section.
Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Peer Comparison 15% · Ownership Trends 10%. Scores use stored reporting periods and are screening indicators, not investment recommendations. Missing dimensions are excluded and the remaining weights are rescaled. At least three dimensions are required for an overall score. Holding movements describe ownership shares, not proven trading flows. Broad industry groups and financial-sector accounting can limit comparability.
Share Price and Basic Stock Data
Last Updated: September 25, 2026, 9:00 pm
| PEG Ratio | -18.15 |
|---|
Understand these figures: how to read the P/E ratio, ROE versus earnings per share, and calculate intrinsic value.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Morepen Laboratories Ltd | 6,593 Cr. | 120 | 127/33.0 | 56.2 | 22.8 | 0.17 % | 8.05 % | 5.33 % | 2.00 |
| Orchid Pharma Ltd | 6,375 Cr. | 1,065 | 1,144/471 | 353 | 300 | 0.00 % | 1.86 % | 1.49 % | 10.0 |
| Sanofi India Ltd | 7,204 Cr. | 3,140 | 4,900/3,049 | 21.0 | 359 | 2.39 % | 57.5 % | 43.0 % | 10.0 |
| IOL Chemicals & Pharmaceuticals Ltd | 5,976 Cr. | 204 | 219/67.1 | 33.8 | 61.3 | 0.49 % | 11.3 % | 8.42 % | 2.00 |
| Bliss GVS Pharma Ltd | 7,506 Cr. | 705 | 734/118 | 54.5 | 113 | 0.21 % | 16.9 % | 11.8 % | 1.00 |
| Industry Average | 23,031.60 Cr | 1,276.48 | 56.79 | 211.60 | 0.38% | 26.16% | 16.59% | 6.06 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 348 | 364 | 401 | 422 | 445 | 423 | 455 | 438 | 453 | 466 | 425 | 412 | 484 |
| Expenses | 328 | 348 | 375 | 388 | 394 | 375 | 404 | 394 | 417 | 424 | 401 | 381 | 438 |
| Operating Profit | 21 | 16 | 26 | 34 | 51 | 48 | 52 | 44 | 36 | 42 | 24 | 31 | 46 |
| OPM % | 6% | 4% | 7% | 8% | 11% | 11% | 11% | 10% | 8% | 9% | 6% | 7% | 10% |
| Other Income | 1 | 3 | 2 | 3 | 4 | 4 | 3 | 5 | 5 | 5 | 4 | 30 | 4 |
| Interest | 1 | 1 | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 5 | 4 | 4 | 4 |
| Depreciation | 7 | 7 | 8 | 8 | 8 | 10 | 6 | 2 | 5 | 16 | 9 | 11 | 10 |
| Profit before tax | 14 | 11 | 21 | 29 | 44 | 42 | 48 | 46 | 35 | 26 | 16 | 46 | 35 |
| Tax % | 36% | 26% | 29% | 26% | 27% | 32% | 25% | 24% | 24% | 21% | 26% | 10% | 22% |
| Net Profit | 9 | 8 | 15 | 21 | 32 | 29 | 36 | 35 | 27 | 20 | 11 | 41 | 28 |
| EPS in Rs | 0.18 | 0.16 | 0.29 | 0.42 | 0.63 | 0.55 | 0.71 | 0.64 | 0.49 | 0.37 | 0.20 | 0.75 | 0.50 |
Last Updated: March 3, 2026, 8:16 pm
Profit & Loss - Annual Report
Last Updated: February 25, 2026, 2:46 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 367 | 401 | 485 | 595 | 607 | 769 | 853 | 1,188 | 1,547 | 1,418 | 1,690 | 1,812 | 1,787 |
| Expenses | 318 | 352 | 424 | 534 | 542 | 701 | 785 | 1,070 | 1,410 | 1,338 | 1,532 | 1,638 | 1,643 |
| Operating Profit | 49 | 48 | 62 | 61 | 65 | 68 | 69 | 119 | 137 | 80 | 159 | 174 | 143 |
| OPM % | 13% | 12% | 13% | 10% | 11% | 9% | 8% | 10% | 9% | 6% | 9% | 10% | 8% |
| Other Income | 4 | 1 | -3 | 4 | 4 | 4 | 9 | 12 | 10 | 6 | 14 | 18 | 43 |
| Interest | 10 | 9 | 10 | 8 | 4 | 2 | 2 | 2 | -7 | 2 | 4 | 8 | 17 |
| Depreciation | 46 | 39 | 35 | 34 | 34 | 40 | 37 | 30 | 28 | 28 | 33 | 29 | 47 |
| Profit before tax | -3 | 2 | 13 | 24 | 30 | 29 | 39 | 99 | 127 | 56 | 135 | 155 | 122 |
| Tax % | 0% | 6% | -1% | 0% | 0% | 1% | 14% | 1% | 20% | 31% | 29% | 24% | |
| Net Profit | -3 | 2 | 13 | 24 | 30 | 29 | 34 | 97 | 102 | 39 | 97 | 118 | 100 |
| EPS in Rs | -0.06 | 0.05 | 0.28 | 0.53 | 0.66 | 0.64 | 0.75 | 2.16 | 2.13 | 0.76 | 1.88 | 2.15 | 1.82 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 9% |
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: July 7, 2026, 5:00 am
| Month | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 96 | 102 | 102 | 110 | 110 |
| Reserves | 78 | 91 | 106 | 136 | 163 | 194 | 335 | 483 | 651 | 745 | 1,047 | 1,137 |
| Borrowings | 201 | 187 | 169 | 134 | 132 | 133 | 17 | 19 | 25 | 29 | 105 | 208 |
| Other Liabilities | 121 | 156 | 173 | 226 | 230 | 246 | 416 | 473 | 332 | 417 | 517 | 482 |
| Total Liabilities | 489 | 524 | 538 | 586 | 615 | 663 | 858 | 1,070 | 1,110 | 1,293 | 1,778 | 1,936 |
| Fixed Assets | 322 | 297 | 272 | 264 | 236 | 216 | 225 | 252 | 267 | 307 | 489 | 513 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 14 | 17 | 24 | 28 | 22 |
| Investments | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 85 | 124 |
| Other Assets | 167 | 227 | 266 | 321 | 379 | 446 | 631 | 804 | 827 | 960 | 1,176 | 1,277 |
| Total Assets | 489 | 524 | 538 | 586 | 615 | 663 | 858 | 1,070 | 1,110 | 1,293 | 1,778 | 1,936 |
Cash Flow
| Month | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 46.00 | 41.00 | 31.00 | 37.00 | 6.00 | -6.00 | 10.00 | -127.00 | -137.00 | -8.00 | -182.00 | -127.00 |
This table and the chart use the Free Cash Flow row from the same stored cash-flow statement. Free cash flow generally measures operating cash flow after capital expenditure; check the source definition and reporting basis. It is not operating profit minus borrowings.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 42 | 51 | 66 | 57 | 73 | 64 | 59 | 56 | 59 | 68 | 70 | 65 |
| Inventory Days | 56 | 55 | 51 | 65 | 76 | 69 | 91 | 82 | 96 | 87 | 85 | 94 |
| Days Payable | 116 | 126 | 140 | 125 | 173 | 124 | 113 | 98 | 90 | 87 | 101 | 114 |
| Cash Conversion Cycle | -17 | -20 | -23 | -3 | -24 | 9 | 37 | 40 | 65 | 69 | 54 | 45 |
| Working Capital Days | -21 | -20 | -10 | -86 | -62 | -34 | -8 | 17 | 55 | 98 | 94 | 107 |
| ROCE % | 1% | 3% | 8% | 9% | 9% | 8% | 10% | 23% | 23% | 8% | 17% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal BSE Healthcare ETF | 4,401 | 0.16 | 0.02 | 4,401 | 2025-04-22 16:00:16 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 2.20 | 1.88 | 0.77 | 2.26 | 2.16 |
| Diluted EPS (Rs.) | 2.20 | 1.88 | 0.77 | 1.96 | 2.16 |
| Cash EPS (Rs.) | 2.68 | 2.54 | 1.30 | 2.71 | 2.83 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 21.10 | 16.58 | 14.72 | 12.10 | 9.43 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 21.10 | 16.58 | 14.72 | 12.10 | 9.43 |
| Revenue From Operations / Share (Rs.) | 33.06 | 33.07 | 27.73 | 32.37 | 26.41 |
| PBDIT / Share (Rs.) | 3.51 | 3.38 | 1.68 | 3.08 | 2.90 |
| PBIT / Share (Rs.) | 2.98 | 2.72 | 1.13 | 2.50 | 2.23 |
| PBT / Share (Rs.) | 2.83 | 2.65 | 1.09 | 2.65 | 2.19 |
| Net Profit / Share (Rs.) | 2.15 | 1.89 | 0.75 | 2.13 | 2.16 |
| NP After MI And SOA / Share (Rs.) | 2.15 | 1.88 | 0.75 | 2.13 | 2.16 |
| PBDIT Margin (%) | 10.62 | 10.21 | 6.04 | 9.50 | 10.99 |
| PBIT Margin (%) | 9.02 | 8.23 | 4.07 | 7.71 | 8.44 |
| PBT Margin (%) | 8.56 | 8.01 | 3.93 | 8.19 | 8.29 |
| Net Profit Margin (%) | 6.51 | 5.71 | 2.72 | 6.57 | 8.17 |
| NP After MI And SOA Margin (%) | 6.51 | 5.68 | 2.72 | 6.57 | 8.17 |
| Return on Networth / Equity (%) | 10.20 | 11.34 | 5.13 | 17.57 | 22.85 |
| Return on Capital Employeed (%) | 12.79 | 15.61 | 7.31 | 19.44 | 22.07 |
| Return On Assets (%) | 6.63 | 7.43 | 3.48 | 9.50 | 11.31 |
| Long Term Debt / Equity (X) | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.06 | 0.03 | 0.03 | 0.03 | 0.03 |
| Asset Turnover Ratio (%) | 1.18 | 1.41 | 1.30 | 1.60 | 1.47 |
| Current Ratio (X) | 2.32 | 2.21 | 2.35 | 1.61 | 1.30 |
| Quick Ratio (X) | 1.72 | 1.59 | 1.64 | 1.00 | 0.87 |
| Inventory Turnover Ratio (X) | 6.60 | 3.70 | 3.10 | 3.53 | 4.01 |
| Interest Coverage Ratio (X) | 23.07 | 46.52 | 43.25 | -19.96 | 73.02 |
| Interest Coverage Ratio (Post Tax) (X) | 15.15 | 27.04 | 20.53 | -12.81 | 55.29 |
| Enterprise Value (Cr.) | 2682.56 | 2126.72 | 1280.99 | 1720.86 | 1393.88 |
| EV / Net Operating Revenue (X) | 1.48 | 1.26 | 0.90 | 1.11 | 1.17 |
| EV / EBITDA (X) | 13.94 | 12.32 | 14.95 | 11.71 | 10.67 |
| MarketCap / Net Operating Revenue (X) | 1.45 | 1.27 | 0.92 | 1.13 | 1.22 |
| Price / BV (X) | 2.27 | 2.54 | 1.74 | 3.02 | 3.40 |
| Price / Net Operating Revenue (X) | 1.45 | 1.27 | 0.92 | 1.13 | 1.22 |
| EarningsYield | 0.04 | 0.04 | 0.02 | 0.05 | 0.06 |
Frequently asked questions
What is the intrinsic value of Morepen Laboratories Ltd and is it undervalued?
Morepen Laboratories Ltd: the stored intrinsic value estimate is ₹31.25, compared with a stored share price of ₹120.00. The model value is 74.0% below that quote. The model classifies this as overvalued; it is an estimate dependent on the inputs and assumptions, not a price target or a buy/sell recommendation. The estimate uses the available valuation models and weights shown in the Intrinsic Value panel, including earnings, cash-flow and asset-based approaches where data permits. It is not a P/E-only calculation.
What share price and 52-week range are shown for Morepen Laboratories Ltd?
The stored share price is ₹120.00. Price-data record updated: 25 September 2026, 9:00 pm +05:30. This is not a live quote. The stored 52-week high / low is 127/33.0; this is a rolling range, not a financial-year range.
How have Morepen Laboratories Ltd's revenue and profit changed?
Revenue for Mar 2025 was ₹1,812.00 Cr, versus ₹1,690.00 Cr in Mar 2024 (7.2% year on year). Net profit for Mar 2025 was ₹118.00 Cr, versus ₹97.00 Cr in Mar 2024 (21.6% year on year). These are the latest annual periods stored on this page; check the quarterly table separately for more recent developments.
Does Morepen Laboratories Ltd's profit convert into cash?
For the same Mar 2025 period, operating cash flow was ₹32.00 Cr against net profit of ₹118.00 Cr. Cash flow covered 0.27 times reported profit. The gap warrants checking receivables, working capital and one-off items in the cash-flow statement.
What should I check in Morepen Laboratories Ltd's balance sheet?
Reported borrowings were ₹208.00 Cr in Mar 2026. Read this alongside cash, interest costs and repayment obligations; reserves are an accounting balance and are not the same as available cash.
How should I compare Morepen Laboratories Ltd's P/E with other stocks?
The stored P/E is 56.20. Compare companies with similar business models, growth, leverage and accounting periods. The industry group on this page is broad, and its average can be affected by outliers. A lower P/E alone does not establish undervaluation.
What could change Morepen Laboratories Ltd's intrinsic value estimate?
Changes in sustainable earnings, cash generation, capital needs, debt and share count can change the estimate. The displayed model uses a 12% cost of equity and 4% terminal growth assumption where applicable. Higher discount rates or weaker growth generally reduce discounted values. Compare the individual model values and weights, and verify fresh filings before relying on the result.